Education
About Us
Working with TipRanks
Follow Us
Sanofi (SNY)
NASDAQ:SNY
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.92Last Year’s EPS
0.95Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: 0.98%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Sanofi's Q1 2025 earnings call presented a strong financial and strategic performance, highlighted by significant growth in Dupixent sales and successful new product launches. However, challenges such as foreign exchange impacts and uncertainties in the U.S. flu vaccine market and potential tariffs present some headwinds.Company Guidance
During the Q1 2025 conference call, Sanofi reported a robust 7% sales growth, driven by strong performances of Dupixent and new launches such as Befortis, which generated EUR 1.1 billion in sales, contributing 11% to total sales. Dupixent alone saw a 20% growth, reaching EUR 3.5 billion, with EUR 2.5 billion from the U.S. market. The vaccine business also showed double-digit growth, bolstered by favorable phasing and new market entries. Sanofi's gross margin improved significantly to 78%, up 2.3 percentage points from the previous year. The company maintained its effective tax rate at 22.3% for Q1, with a full-year expectation of around 20%. Business EPS increased by 15.7% to EUR 1.79, supported by strong sales and operational efficiencies. Additionally, Sanofi announced progress in its sustainability strategy and outlined plans for continued investment in R&D and strategic acquisitions, alongside a EUR 5 billion share buyback program, 76% of which was completed by the date of the call.Strong Start to 2025
Sanofi reported a 7% sales growth in Q1 2025 driven by pharma launches, Dupixent, and Befortis in the vaccines portfolio. New launches contributed EUR 1.1 billion in sales, 11% of the total.
Dupixent Growth
Dupixent sales grew by 20% in Q1, reaching EUR 3.5 billion. U.S. sales were EUR 2.5 billion, up 18%. Dupixent leads in total prescription share across all approved indications.
Vaccines Segment Performance
Vaccines business delivered double-digit growth in Q1, driven by favorable Fortis phasing and new country launches.
Financial Performance
Net sales increased by 9.7% at constant exchange rates to EUR 9.9 billion. Gross margin improved to 78%, up 2.3 percentage points. Business EPS was EUR 1.79, up 15.7%.
Pipeline and Approvals
Sanofi obtained 6 approvals in Q1, including for Dupixent in COPD in Japan and CSU in the U.S. and Sarclisa in several countries.
---
SNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 24, 2025 | $53.02 | $53.54 | +0.98% |
| Jan 30, 2025 | $52.15 | $54.15 | +3.84% |
| Oct 25, 2024 | $52.05 | $54.34 | +4.40% |
| Jul 25, 2024 | $51.20 | $53.10 | +3.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sanofi (SNY) report earnings?
Sanofi (SNY) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Sanofi (SNY) earnings time?
Sanofi (SNY) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNY EPS forecast?
SNY EPS forecast for the fiscal quarter 2025 (Q1) is 0.92.
---
